Latest Us Market News

Stakk Limited reports a striking 158% year-over-year revenue increase in FY25, driven by its Embedded Finance solutions and strategic partnerships. The company’s pivot from B2C to B2B signals a focused growth trajectory into FY26.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Atomos Ltd reported a 9% revenue decline to $32.7 million for FY25 but improved its loss after tax by 35%, driven by cost restructuring and tighter expense control amid challenging market conditions.

OMG Group Limited reported a robust 63.3% revenue increase to $4.13 million in FY2025, driven by strategic acquisitions and expanded retail partnerships. The company also narrowed its losses by 29%, setting the stage for sustained growth in FY2026.

Uscom Limited reported a 25% decline in revenue to $3.16 million and a 59% increase in net loss to $3.3 million for FY25, reflecting significant global headwinds. Despite setbacks, the company advanced new product approvals and secured funding to navigate ongoing challenges.

TZ Limited reported a challenging FY25 with a $3.52 million net loss, impacted by integration costs and US tariff disruptions. Despite setbacks, the company completed the Keyvision acquisition and anticipates a strong revenue rebound in FY26.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Pengana Private Equity Trust reported a robust FY25 with a 7.6% NAV increase and a strong net profit of $50 million, underpinned by a diversified global private equity portfolio and a strategic buyback program.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.